Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease

Abstract

Background: Little is known about long-term real-world effectiveness of vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease (IBD). Methods: Biologic-naive IBD patients who received vedolizumab or infliximab in the US Explorys Universe database (May 2014-September 2018) were weighted using Entropy-balancing. Results: Persistence rates were higher for vedolizumab (N = 542) versus infliximab (N = 1,179) cohort at 12 (84.5% vs 77.5%; P = 0.0061) and 24 (77.6% vs 64.6%; P = 0.0005) months post-maintenance therapy. Healthcare resource utilization composite end point rates were lower in vedolizumab versus infliximab cohort at 12 (36.2% vs 48.2%; P < 0.0001) and 24 (46.9% vs 59.9%; P < 0.0001) months post-treatment initiation. Conclusions: Biologic-naive IBD patients who received vedolizumab had better long-term real-world effectiveness measures versus infliximab patients.